Praxis Precision Medicines adds Jill DeSimone to its Board of Directors

– USA, MA –  Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company today announced the appointment of Jill DeSimone to its board of directors.

“Jill’s background as a multi-faceted business leader and passion for bringing innovative treatments to people in need will be a tremendous addition to the Praxis board. We look forward to working closely with her and applying her unique know-how during a particularly exciting period for Praxis and moving forward,” said Board Chairman, Dean Mitchell.

CEO, Marcio Souza added, “We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence in patient care.”

About Jill DeSimone

Ms. DeSimone served as president of U.S. Oncology at Merck & Co., Inc. from 2014 to May 2022. During her time at Merck, Ms. DeSimone also temporarily served as interim president of U.S. Pharma to help navigate the business through the COVID-19 pandemic. Before joining Merck, she served as SVP of Global Women’s Health at Teva Pharmaceutical Industries Ltd from 2012 to 2014. Before her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including SVP of U.S. Commercial from 2010 to 2012 and SVP of U.S. Virology/HIV from 2006 to 2010. Ms. DeSimone serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that helps individuals with their essential living expenses while they undergo cancer treatment.

“I am honored to join the board at Praxis, as they continue their efforts to help people living with CNS conditions,” said Ms. DeSimone. “Throughout my career, I have focused largely on areas of high unmet need, including most recently building and overseeing Merck’s U.S. oncology business. The opportunity with Praxis allows me to continue to follow my passion and share my expertise in product launches for both rare and more common diseases.”

Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders, and epilepsy, with three clinical-stage product candidates.

For more information: https://praxismedicines.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team